[{"id":"be22e26d-8845-4841-a89a-4b805385dc5f","acronym":"A534260","url":"https://clinicaltrials.gov/study/NCT03958383","created_at":"2021-01-18T19:28:46.700Z","updated_at":"2025-02-25T14:28:23.067Z","phase":"Phase 1/2","brief_title":"IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma","source_id_and_acronym":"NCT03958383 - A534260","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" IL2","pipe":" | ","alterations":" PD-L1 expression","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • lorukafusp alfa (APN301)"],"overall_status":"Suspended","enrollment":" Enrollment 61","initiation":"Initiation: 01/30/2020","start_date":" 01/30/2020","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2026","study_completion_date":" 08/15/2026","last_update_posted":"2024-09-19"},{"id":"76bcee8d-d0c5-4e24-bb8d-d22c3dc8e97d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03209869","created_at":"2021-01-18T15:49:47.987Z","updated_at":"2024-07-02T16:36:04.084Z","phase":"Phase 1","brief_title":"Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2","source_id_and_acronym":"NCT03209869","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lorukafusp alfa (APN301)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/12/2018","start_date":" 03/12/2018","primary_txt":" Primary completion: 09/07/2022","primary_completion_date":" 09/07/2022","study_txt":" Completion: 09/07/2022","study_completion_date":" 09/07/2022","last_update_posted":"2022-09-13"},{"id":"cac20d08-9711-4da9-b7b4-75cfc0c4d186","acronym":"","url":"https://clinicaltrials.gov/study/NCT00590824","created_at":"2021-01-18T02:11:08.178Z","updated_at":"2024-07-02T16:36:53.336Z","phase":"Phase 2","brief_title":"Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma","source_id_and_acronym":"NCT00590824","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" IL2 • CRP","pipe":"","alterations":" ","tags":["IL2 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lorukafusp alfa (APN301)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 12/17/2007","start_date":" 12/17/2007","primary_txt":" Primary completion: 09/20/2018","primary_completion_date":" 09/20/2018","study_txt":" Completion: 09/20/2018","study_completion_date":" 09/20/2018","last_update_posted":"2019-11-21"},{"id":"d86c8bcf-cef4-4609-9535-ccff3069fc89","acronym":"","url":"https://clinicaltrials.gov/study/NCT00109863","created_at":"2021-01-18T00:21:32.846Z","updated_at":"2024-07-02T16:36:53.468Z","phase":"Phase 2","brief_title":"Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma","source_id_and_acronym":"NCT00109863","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lorukafusp alfa (APN301)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 05/01/2005","start_date":" 05/01/2005","primary_txt":" Primary completion: 07/01/2007","primary_completion_date":" 07/01/2007","study_txt":" Completion: 02/01/2014","study_completion_date":" 02/01/2014","last_update_posted":"2019-11-19"},{"id":"143d0119-ea7f-43c4-9920-f786eb911284","acronym":"","url":"https://clinicaltrials.gov/study/NCT01334515","created_at":"2021-01-18T05:26:30.400Z","updated_at":"2024-07-02T16:36:54.399Z","phase":"Phase 2","brief_title":"Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma","source_id_and_acronym":"NCT01334515","lead_sponsor":"Children's Oncology Group","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim) • lorukafusp alfa (APN301)"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 12/31/2013","primary_completion_date":" 12/31/2013","study_txt":" Completion: 09/30/2019","study_completion_date":" 09/30/2019","last_update_posted":"2019-10-21"}]